- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01422252
Evaluation of a Fall Detection Device in Isolated Elderly (VIGI91)
Evaluation of Falls Occurring at Home in People Over 75 Equipped or Non-equipped With a Precocious Detection Device. Prospective Interventional Study.
Study Overview
Detailed Description
Objectives of the study:
Principal objective : To evaluate the evolution 6 months after a fall occurring at home in people over 75 equipped or non-equipped with a precocious detection device. Prospective interventional study.
Secondary objective : To establish a relation between the alert emitted by the device, the time separating the fall from the arrival at hospital and the potential MORBI-mortality To describe the sequences of intervention of the different operators Methodology :Multicenter, prospective, cohort, interventional study. Pattern of the study : The study will comprehend 2 visits to be realized in a 10-month interval.
Visits:
- Randomization, inclusion and selection visit(Visit 1): The inclusion of the subject will be effective once the enlightened consent signed, after check of the inclusion criteria. Inclusion and standardized questioning will be realized by the medical evaluators. The data will be obtained by questioning the subject and if need be of relatives and GP. The questioning will be carried out with a questionnaire on independent card comprising the frailty elements. Independently, a follow-up will be operated at home by a nurse of HPGM Les Magnolias hospital for the maintenance of the adhesive patch to be changed regularly nearly every 10 days in the persons equipped, the study plans the installation of Vigi'Fall® device as the only peculiar measure during the coverage. At the conclusion of that first report, the whole questionnaires will be picked up again by a participant in charge of completing the potential missing data. Via this colligation of missing data, the exhaustiveness of the data will be automatically checked.
End of study visit (Visit 2): 10 months 10 months after the installation of Vigi'Fall® device, a contact will be established with the subject and if need be relatives and GP to be informed of the evolution but as well the appearance of potential falls with their characteristics.
- Relation between alert, intervention time and evolution : Theses relations will be investigated with the most possible accuracy. The standardized questioning will be completed by an investigator up to a maximal exhaustiveness.
- Description of the sequences of intervention:These sequences will be evaluated via a simple and standardized questionnaire.
- Expected results, perspectives and scientific data: To quantify with accuracy the evolution in persons over 75 equipped with a precocious detection device after a fall occurring at home in comparison with a witness population non equipped. To establish a relation between the alert emitted by the device, the time separating the fall from the arrival at hospital and the potential MORBI-mortality. To describe with the most possible accuracy the time sequences of the different operators To quantify the rate of subjects hospitalized (with the duration of hospitalization), of subjects still living at home or having left to be admitted in institution (nursing home, retirement home...) in the different groups. The information hence obtained will enable a better knowledge of the tools for detection and precocious alert in falls of the elderly.
- Direct benefit for geriatricians, sanitary and care professionals and emergency physicians:
Change in practices :Prevision of subjects likely to benefit of a precocious detection device. Development of prevention in hospital geriatric departments, geriatric care networks, emergency departments and local services for the elderly and disabled (SDPAH).
Education : Sensitize the medical, paramedical and social teams to the usefulness of precocious detection devices in elderly subjects at risk for falls.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75014
- Cochin Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Person over 75 living at home alone in ESSONNE (France) and having fallen at least one time during the 3 months preceding the inclusion in the study.
- Person having signed a free and enlightened consent
Exclusion Criteria:
- Person living in institution (nursing home, retirement home...)
- Person under 75
- Person with severe cognitive impairment (MMS < 15)
- Person under protection as incapable (guardianship or trusteeship)
- Person not affiliated to a social insurance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Persons equipped
Precocious fall detection device
|
Precocious fall detection device
|
|
No Intervention: Persons non-equipped
No fall detection device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Death
Time Frame: 6 months
|
The death 6 months after a recurrent fall
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time between the fall and the arrival of emergency
Time Frame: 13 months
|
The time between the fall and the arrival of emergency will be compared in both groups.
|
13 months
|
|
Hospitalization
Time Frame: 13 months
|
The rate of subjects hospitalized (with the duration of hospitalization)
|
13 months
|
|
Follow up of patients
Time Frame: 13 months
|
The rate of subjects still living at home or having left to be admitted in an institution (nursing home, retirement home...).
|
13 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Yann-Erick Claessens, MD, PhD, Hopital Cochin
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- P100202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Elderly
-
University of Rome Foro ItalicoCompletedAging | Elderly | Frail Elderly | Aging Frailty | Sarcopenia in ElderlyItaly
-
DSM Nutritional Products, Inc.CompletedFrail Elderly | Pre-frail ElderlyNetherlands
-
Maimonides Medical CenterCompletedElderly | Frail Elderly | Hospitalization | Geriatrics
-
University of ThessalyCompletedFunctionality, Falls, Elderly, Fall Prevention, Exercise Elderly, Assessment, Rehabilitation, Community-DwellingGreece
-
Indian Council of Medical ResearchSt Johns Medical College Hospital, Bangalore, IndiaRecruiting
-
Burdur Mehmet Akif Ersoy UniversityPamukkale UniversityCompleted
-
Hospital Israelita Albert EinsteinConselho Nacional de Desenvolvimento Científico e Tecnológico; Paulo de Tarso...Completed
-
Istanbul Medipol University HospitalCompleted
-
Seoul National University HospitalCompleted
-
Purdue UniversityCompleted
Clinical Trials on Vigi'Fall®
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownFunctional DyspepsiaKorea, Republic of
-
Amir AzarpazhoohInstitut Straumann AGCompletedPeriodontal Inflammation | Crown LengtheningCanada
-
Novartis PharmaceuticalsCompletedPulmonary Disease, Chronic Obstructive (COPD)Argentina
-
GuerbetCompletedPrimary Brain TumorColombia, Korea, Republic of, United States, Mexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussisUnited States